GlassScriptPhysician profile
Reena Vinod Jayani-Kosarzycki
NPI 1922397561
$1,103.91
in general payments reported to CMS, 2019-2025
14 companies · $585 in 2025
The $585 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $181 · 2020: $113 · 2022: $38.00 · 2024: $187 · 2025: $585.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $771.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $771.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $145.79 | 2024-2025 | |
| Pfizer INC. | $135.37 | 2025 | |
| Rigel Pharmaceuticals, INC. | $130.82 | 2025 | Rezlidhia, Gavreto, Tavalisse |
| Medexus Pharma, INC. | $126.93 | 2025 | Grafapex |
| Novo Nordisk INC | $117.64 | 2025 | Ozempic |
| Kite Pharma, INC. | $113.19 | 2020 | |
| Genzyme Corporation | $98.34 | 2019 | |
| Novartis Pharmaceuticals Corporation | $94.06 | 2024 | |
| Spectrum Pharmaceuticals INC. | $59.07 | 2019 | |
| Janssen Pharmaceuticals, INC | $38.00 | 2022 | |
| Celgene Corporation | $23.86 | 2019 | |
| Abbvie INC. | $20.84 | 2024 |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Reena Jayani-Kosarzycki listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.